Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
2.265
-0.205 (-8.30%)
May 14, 2025, 4:00 PM - Market closed
Mainz Biomed Stock Forecast
MYNZ's stock price has decreased by -91.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Mainz Biomed stock has a target of 14, which predicts a 518.10% increase from the current stock price of 2.27.
Price Target: $14.00 (+518.10%)
Analyst Consensus: Buy
* Price targets were last updated on Feb 14, 2025.
Analyst Ratings
The average analyst rating for Mainz Biomed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +518.10% | Feb 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 25, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $120 | Strong Buy | Maintains | $200 → $120 | +5,198.01% | Mar 6, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 21, 2023 |
Financial Forecast
Revenue This Year
1.28M
from 893.99K
Increased by 42.95%
Revenue Next Year
1.18M
from 1.28M
Decreased by -7.43%
EPS This Year
-6.68
from -22.36
EPS Next Year
-1.92
from -6.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.5M | 1.2M | 2.9M | ||
| Avg | 1.3M | 1.2M | 2.8M | ||
| Low | 1.1M | 1.1M | 2.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 64.4% | -4.7% | 143.7% | ||
| Avg | 43.0% | -7.4% | 136.8% | ||
| Low | 21.1% | -11.0% | 127.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -4.10 | -1.97 | -2.09 |
| Avg | -6.68 | -1.92 | -2.03 |
| Low | -9.02 | -1.84 | -1.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.